Status:
COMPLETED
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
Lead Sponsor:
Ipsen
Conditions:
Turner Syndrome
Renal Insufficiency, Chronic
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
Eligibility Criteria
Inclusion
- Children under 18 with growth failure associated with inadequate growth hormone secretion, or Turner syndrome or chronic renal insufficiency.
Exclusion
- Children with closed epiphyses
- Children with active neoplasm
- Children with acute critical illness
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT00234533
Start Date
June 1 2004
End Date
July 1 2008
Last Update
December 9 2019
Active Locations (45)
Enter a location and click search to find clinical trials sorted by distance.
1
Dienst Kindergeneeskunde
Brussels, Belgium, B-1090
2
Dienst Kindergeneeskunde
Edegem, Belgium, B-2650
3
Klinika Deti a Dorostu
Prague, Czechia, 100 34
4
Aalborg Sygehus Nord, Borneafdelingen
Aalborg, Denmark, 9100